Biomedical Papers - Epub Ahead of Print

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. X:X | 10.5507/bp.2013.093

Pathophysiology of anemia in chronic kidney diseases. A review

Josef Zadrazil, Pavel Horak
Department of Internal Medicine III - Nephrology, Rheumatology and Endocrinology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic

Backgroud. Anemia is one of the laboratory and clinical findings of chronic kidney diseases (CKD). The presence of anemia in patients with CKD has a wide range of clinically important consequences. Some of the symptoms that were previously attributed to reduced renal function are, in fact, a consequence of anemia. Anemia contributes to increased cardiac output, the development of left ventricular hypertrophy, angina, and congestive heart failure. According to current knowledge, anemia also contributes to the progression of CKD and is one of the factors that contribute to the high morbidity and mortality in patients with chronic renal failure and their reduced survival.

Methods: MEDLINE search was performed to collect both original and review articles addressing anemia in CKD, pathophysiology of renal anemia, erythropoiesis, erythropoietin, iron metabolism, inflammation, malnutrition, drugs, renal replacement therapy and anemia management

Conclusion: The present review summarized current knowledge in the field of the pathophysiology of renel anemia. Understanding the pathophysiology of anemia in CKD is crucial for the optimal treatment of anemia according to recent clinical practice guidelines and recommendation, and correct recognition of causes of resistence to treatment of erythropoietin stimulating agents (ESA).

Keywords: anemia, chronic kidney diseases, erythropoietin, irone metabolism, erythropoiesis

Received: August 20, 2013; Accepted: December 11, 2013; Published: January 3, 2014


References

  1. Eschbach JW. The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietin. Kidney Int 1989;35:134-48. Go to original source... Go to PubMed...
  2. Eckardt KU. Erythropoiesis and its failure in renal dinase. Nephron 1994;67:7-23. Go to original source... Go to PubMed...
  3. Johansen KL, Finkelstein FO, Revicki DA, Gitlin M, Evans C, Mayne TJ. Systematic review and meta-analysis of exercise tolerance and physical functioning in dialysis patients treated with erythropoiesis-stimulating agents. Am J Kidney Dis 2010; 55:535-48. Go to original source... Go to PubMed...
  4. Patel TV, Singh AL. Anemia in chronic kidney disease: new advances. Heart Fail Clin 2010; 6:347-57. Go to original source... Go to PubMed...
  5. Suzuki M, Hada Y, Akaishi M, Hiroe M, Aonuma K, Tsubakihara Y, Akizawa T. Effect of anemia correction by erythropoiesis-stimulating agents on cardiovascular function in non-dialysis patients with chronic kidney disease. Int Heart J 2012;53:238-43. Go to original source... Go to PubMed...
  6. Eckardt KU. Biology of erythropoietin production. Nephrol Dial Transplant 1995;10:2572-4. Go to PubMed...
  7. Frede S, Freitag P, Geuting L, Konietzny R, Fandrey J. Oxygen-regulated expression of the erythropoietin gene in the human renal cell line REPC. Blood 2011;117:4905-14. Go to original source... Go to PubMed...
  8. Jelkmann W. Regulation of erythropoietin production. J Physiol 2011;589:1251-8. Go to original source... Go to PubMed...
  9. Walle AJ, Wong GY, Clemons GK, Garcia JF, Niedermayer W. Erythropoietin - hematocrit feedback circuit in the anemia of end-stage renal disease. Kidney Int 1987;31: 1205-9. Go to original source... Go to PubMed...
  10. Nangaku M, Eckardt KU. Pathogenesis of renal anemia. Semin Nephrol 2006;26:261-8. Go to original source... Go to PubMed...
  11. Jelkmann W. Erythropoietin after a century of research: younger than ever. Eur J Haematol 2007;78:183-205. Go to original source... Go to PubMed...
  12. Lin F, Suggs S, Lin C, Browne JK, Smalling R, Egrie JC, Chen KK, Fox GM, Martin F, Stabinsky Z. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 1985;82:7580-7. Go to original source... Go to PubMed...
  13. Kapitsinou PP, Liu Q, Unger TL, Rha J, Davidoff O, Keith B, Epstein JA, Moores SL, Erickson-Miller CL, Haase VH. Hepatic HIF-2 regulates erythropoietin responses to hypoxia in renal anemia. Blood 2010;116:3039-48. Go to original source... Go to PubMed...
  14. Ratcliffe PJ, Ebert BJ, Ferguson DJP, Firth JD, Gleadle JM, Maxwell PH, Pugh CW. Regulation of the erythropoietin gene. Nephrol Dial Transplant 1995;10:18-27. Go to original source... Go to PubMed...
  15. Huang LE, Ho V, Arany Z, Krainc D, Galson D, Tendler D, Livingston DM, Bunn HF. Erythropoietin gene regulation depends on heme-dependent oxygen sensing and assembly of interacting transcription factors. Kidney Int 1997;51:548-52. Go to original source... Go to PubMed...
  16. Maxwell PH, Ferguson DJP, Nicholls LG, Iredale JP, Pugh CW, Johnson MH, Ratcliffe PJ. Sites of erythropoietin production. Kidney Int 1997;51:393-401. Go to original source... Go to PubMed...
  17. Maxwell PH, Ferguson DJP, Nicholls LG, Johnson MH, Ratcliffe PJ. The interstitial response to renal injury: Fibroblast - like cells show phenotypic changes and have reduced potential for erythropoietin gene expression. Kidney Int 1997;52:715-24. Go to original source... Go to PubMed...
  18. Lacombe C, Da Silva JL, Bruneval P. Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney. J Clin Invest 1988;81:620-3. Go to original source... Go to PubMed...
  19. Koury ST, Bondurant MC, Koury MJ. Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization. Blood 1988;71:524-7. Go to PubMed...
  20. Vokurka M. Fyziologie a patofyziologie erytropoezy II: Regulace a erytropoetin. Aktuality v nefrologii 2011;17:96-102.
  21. Epstein FH. Oxygen and renal metabolism. Kidney Int 1997;51:381-5. Go to original source... Go to PubMed...
  22. Youssoufian H, Langomore G, Neumann D, Yoshimura A, Lodish HF. Structure, fuction and activation of the erythropoietin receptor. Blood 1993;81:2223-36. Go to PubMed...
  23. Erslev AJ, Besarab A. Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure. Kidney Int 1997;51:622-30. Go to original source... Go to PubMed...
  24. Del Vecchio L, Cavalli A, Tucci B, Locatelli F. Chronic kidney disease-associated anemia: new remedies. Curr Opin Investig Drugs 2010;11:1030-8. Go to PubMed...
  25. Fried W. Erythropoietin and erythropoiesis. Exp Hematol 2009;37:1007-15. Go to original source... Go to PubMed...
  26. Krause A, Neitz S, Magert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, Adermann K. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett 2000;480:147-50. Go to original source... Go to PubMed...
  27. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptidesynthezided ion the liver. Journal of Biol Chem 2001;384:245-53. Go to original source...
  28. Ganz T, Nemeth E. Hepcidin and Disorders in Iron Metabolism. Annu Rev Med 2011;18:347-60. Go to original source...
  29. Tessitore N, Girelli D, Campostrini N, Bedogna V, Pietro Solero G, Castagna A, Melilli E, Mantovani W, De Matteis G, Olivieri O, Poli A, Lupo A. Hepcidin is not useful as a biomerker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents. Nephrol Dial Transplant 2010;25:3996-4002. Go to original source... Go to PubMed...
  30. Cook JD, Shikne BS. Iron deficiency: Definition and diagnosis. J Intern Med 1989;226: 349-355. Go to original source... Go to PubMed...
  31. Fishbane S, Maesaka JK. Iron Management in End-Stage Renal Disease. Am J Kidney Dis 1997;29:319-33. Go to original source... Go to PubMed...
  32. Besarab A, Coyne DW. Iron supplementation to treat anemia in patients with chronic kidney disease. Nat Rev Nephrol 2010;6:699-710. Go to original source... Go to PubMed...
  33. Besarab B. Anemia and iron management. Semin Dial 2011;24:498-503. Go to original source... Go to PubMed...
  34. Zadrazil J, Papajik T, Bachleda P, Budikova M, Novotny D, Scudla V. Ucast nedostatku zeleza na rozvoji chudokrevnosti u nemocnych v pravidelnem dialyzacnim leceni. Vnitrni Lek 1994;40:362-6.
  35. Laufberger V. Sur la cristallisation de la ferritine. Soc Chim Biol 1937;18:1575-82.
  36. Vokurka M. Fyziologie a patofyziologie erytropoezy I: Metabolizmus zeleza. Aktuality v nefrologii 2011;17:63-8.
  37. Addison GM, Beamish MR, Hales CN, Hodgkins M, Jacobs A, Liewellin P. An immunoradiometric assay for ferritin in the serum of normal subjects and patients with iron deficiency and iron overload. J Clin Pathol 1972;25:326-9. Go to original source... Go to PubMed...
  38. Goldwasser P, Koutelos T, Abraham S, Avram MM. Serum ferritin, hematocrit and mean corpuscular volume in hemodialysis. Nephron 1994;67:30-5. Go to original source... Go to PubMed...
  39. Ford BA, Coyne DW, Eby CS, Scott MG. Variability of ferritin measurements in chronic kidney disease; implications for iron management. Kidney Int 2009;75:104-10. Go to original source... Go to PubMed...
  40. Gkouvatsos K, Papanikolaou G, Pantopoulos K. Regulation of iron transport and the role of transferrin. Biochim Biophys Acta 2012;1820:188-202. Go to original source... Go to PubMed...
  41. Luck AN, Mason AB. Transferrin-mediated cellular iron delivery. Curr Top Membr 2012;69:3-35. Go to original source... Go to PubMed...
  42. Wessling-Resnick M. Iron homeostasis and the inflammatory response. Annu Rev Nutr 2010;30:105-22. Go to original source... Go to PubMed...
  43. Roy CN. Anemia of inflammation. Hematology Am Soc Hematol Educ Program 2010; 2010:276-80. Go to original source... Go to PubMed...
  44. De Lima GA, Mazzali M, Gentil AF, Plotegher L, Grotto HZ. Anemia in chronic renal disease: evaluation of inflammatory activity on erythropoiesis and iron metabolism in patients not submitted to dialysis treatment. Clin Lab 2012;58:695-704. Go to PubMed...
  45. Rambod M, Kovesdy CP, Kalantar-Zadeh K. Combined high serum ferritin and low iron saturation in hemodialysis patients: the role of inflammation. Clin J Am Soc Nephrol 2008;3:1691-701. Go to original source... Go to PubMed...
  46. Cooper AC, Mikhail A, Lethbridge MW, Kemeny DM, MacDougall IC. Increased expression of erythropoiesis inhibiting cytokines (IFN-γ, TNF-α, IL-10 and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy. J Am Soc Nephrol 2003;14:1776-84. Go to original source... Go to PubMed...
  47. Wallner SF, Vantrin RM. Evidence that inhibition of erythropoiesis is important in the anemia of chronic renal failure. J Lab Clin Med 1981;97:170-8. Go to PubMed...
  48. Kushner D, Beckman B, Nquyen L, Chen S, Della Santina C, Husserl F, Rice J, Fisher JW. Polyamines in the anemia of end-stage renal disease. Kidney Int 1991;31:725-32. Go to original source...
  49. Brunati C, Cappellini MD, De Feo T, Guastoni C, Ballerini L, Busnach G, Civati G, Fiorelli G, Minetti L. Uremic inhibitor of erythropoiesis. A study during treatment with recombinant human erythropoietin. Am J Nephrol 1992;12:9-13. Go to original source... Go to PubMed...
  50. Erslev AJ, Besarab A. The rate and control of baseline red cell production in hematologically stable patients with uremia. J Lab Clin Med 1995;126:283-6. Go to PubMed...
  51. Teschner M, Kosch M, Schaefer RM. Folate metabolism in renal failure. Nephrol Dial Transplant 2002;17:24-7. Go to original source... Go to PubMed...
  52. Elliott J, Mishler D, Agarwal R. Hyporesponsiveness to erythropoietin: causes and management. Adv Chronic Kidney Dis 2010;17:94-100. Go to original source... Go to PubMed...
  53. Alfrey AC, Legendre GR, Kaehny WD. The dialysis encephalopathy syndrome. Possible aluminium intoxication. N Engl J Med 1976;294:184-8. Go to original source... Go to PubMed...
  54. Elliot HL, MacDougall AJ. Aluminium studies in dialysis encephalopathy. Proc Eur Dial Transplant Assoc 1978;15:157-63. Go to PubMed...
  55. Pierides AM. Haemodialysis osteodystrophy with osteomalacia as the main finding-relation to aluminium intoxication. Clacif Tissue Res 1980;31:453-65.
  56. Schwartz R, Dombrouski J, Kluin K. Microcytic anemia and aluminium toxicity. Kidney Int 1985;27:128-33.
  57. Altmann P, Plowman D, Marsh F, Cunningham J. Aluminium chelatation therapy in dialysis patiens: Evidence for inhibition of hemoglobin synthesis by low levels of aluminium. Lancet 1988;1:1012-15. Go to original source... Go to PubMed...
  58. Bhadada SK, Bhansali A, Ahluwalia J, Chanukya GV, Behera A, Dutta P. Anemia and marrow fibrosis in patinets with primary hyperparathyreoidism before and after curative parathyreoidectomy. Clin Endocrinol 2009;70:527-32. Go to original source... Go to PubMed...
  59. Limrick C, McNichols-Thomas C. Anaemia and mineral bone disorder in chronic kidney disease: a review of the current literature and implication for clinical nursing practice. J Ren Care 2009;35:94-100. Go to original source... Go to PubMed...
  60. Hess E, Sperschneider H, Stein G. Do ACE inhibitors influence the dose of human recombinant erythropoietin in dialysis patients? Nephrol Dial Transplant 1996;11:749-51. Go to original source... Go to PubMed...
  61. Vlahakos DV, Marathias KP, Madias NE. The role of the renin-angiotensin system in the regulation of erythropoiesis. Am J Kidney Dis 2010;56:558-65. Go to original source... Go to PubMed...
  62. Malyszko J., Oberbauer R., Watschinger B. Anemia and erythrocytosis in patient after kidney transplatnation. Transplant Int 2012;25:1013-23 Go to original source...
  63. Gaweda AE, Goldsmith LJ, Brier ME. Aronoff GR. Iron, inflammation, dialysis adequacy, nutritional status, and hyperparathyreodism modify erythropoietic response. Clin J Am Soc Nephrol 2010;5:576-81. Go to original source... Go to PubMed...
  64. KDIGO Clinical Practice for Anemia in. Chronic Kidney Disease. Kidney Int 2012, 2 (Suppl 4):279-366.